ePT--the Electronic Newsletter of Pharmaceutical Technology, Jan 31, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jan 31, 2013
News
Ben Venue Laboratories Enters Consent Decree
By Amy Ritter
Ben Venue Laboratories announced that it has voluntarily entered into a consent decree with FDA over violations of cGMP.
GSK in Joint Venture for Pediatric Vaccine
By Stephanie Sutton
GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination pediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.
Actavis Unveils Long-Term Growth Strategy
By Christopher Allen
Following its recent acquisition, Actavis (formerly Watson Pharmaceuticals) unveiled its long-term growth strategy during its investor meeting in New York.
AstraZeneca and Ceram Sign R&D Agreement
By Stephanie Sutton
AstraZeneca and Ceram Research, a materials development company based in the UK, have signed an agreement whereby Ceram will develop its inorganic-based controlled release technology in a feasibility study for delivering select AstraZeneca compounds.
Allergan to Acquire MAP Pharmaceuticals
By Adeline Siew, PhD
Allergan and MAP Pharmaceuticals have entered into a definite merger agreement under which Allergan will purchase all of MAP?s outstanding shares for the price of $25.00 per share.
Regulatory Roundup for the Week of January 28, 2013
EMA announces collaboration with Israel, and USP updates chapter on elemental impurities.
Industry Briefs: January 28, 2013
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here